Lercanidipina Doc Generici

Lercanidipine, the active ingredient in Lercanidipina Doc Generici, is a calcium channel blocker presented as an oral tablet for systemic use. It is employed to lower elevated blood pressure in adult patients with hypertension.

GNH USA supplies Lercanidipina Doc Generici as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics across global markets with consistent quality and regulatory compliance. The company ensures reliable delivery, appropriate documentation, and support for regulatory approvals.

Lercanidipine is indicated for the management of arterial hypertension, acting on vascular smooth muscle to achieve blood‑pressure control.

- Hypertension: reduces elevated systolic and diastolic blood pressure in adult patients. - Essential hypertension: provides sustained arterial vasodilation to improve long‑term cardiovascular risk. - Isolated systolic hypertension: lowers high systolic pressure while maintaining diastolic stability.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: warmth and redness, usually resolves without intervention. - Peripheral edema: swelling of ankles or feet due to fluid accumulation. - Dizziness: sensation of light‑headedness, especially after standing. - Fatigue: general feeling of tiredness. - Tachycardia: increased heart rate without accompanying symptoms.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure causing fainting or shock. - Myocardial infarction: rare occurrence of heart attack. - Hepatic injury: abnormal liver function tests or jaundice. - Allergic reactions: rash, itching, or anaphylaxis.

Before initiating therapy, clinicians should consider several safety aspects.

- Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: use with caution; liver disease may alter drug metabolism. - Concomitant strong CYP3A4 inhibitors: increased plasma levels may lead to excessive hypotension. - Pregnancy: safety not established; avoid unless clearly indicated. - Elderly patients: higher susceptibility to orthostatic hypotension; start at low dose and monitor. - Store at below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Lercanidipine can interact with several medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Cyclosporine: may raise lercanidipine concentrations, increasing hypotensive risk. - Grapefruit juice: potent CYP3A4 inhibition can cause excessive drug levels. - Strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole): risk of severe hypotension.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: additive blood‑pressure lowering effect; monitor heart rate. - Diuretics: may enhance orthostatic hypotension; adjust fluid status. - Simvastatin: increased statin exposure; watch for muscle toxicity.